A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Forehead Lines
Interventions
DRUG

OnabotulinumtoxinA

Intramuscular Injections

DRUG

Placebo

Intramuscular Injections

Trial Locations (15)

732-0053

Hiroshima Station Clinic /ID# 268467, Hiroshima

063-0812

Kotoni Tower Skin And Cosmetic Surgery Clinic /ID# 268460, Sapporo

259-1193

Tokai University Hospital /ID# 268496, Isehara

220-6208

Queen's Square Medical Center, Dermatology and Allergology /ID# 268454, Yokohama

380-0826

Jun Clinic /ID# 268531, Nagano

900-0015

Touyama Plastic Surgery Clinic /ID# 268456, Naha

569-0824

Yoshikawa Skin Clinic /ID# 268494, Takatsuki

103-0027

Tokyo Center Clinic /ID# 268477, Chuo-ku

104-0031

Tokyo Asbo Clinic /ID# 268529, Chuo-ku

104-0061

Ginza Skin Clinic /ID# 268532, Chuo-ku

108-8642

Kitasato University Kitasato Institute Hospital /ID# 268499, Minato-ku

117-0041

Forest Palace Dermatology Clinic /ID# 268599, Nerima-ku

190-0023

Greenwood skin clinic Tachikawa /ID# 268528, Tachikawa-shi

333-0055

Chiharu Dermatology Clinic Urawa /ID# 268497, Saitama

101-0021

Akihabara Skin Clinic /ID# 268441, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY